Amylyx Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024: USD -80.08 M

Amylyx Pharmaceuticals, Inc. EBITDA is USD -80.08 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -48.31% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Amylyx Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -154.92 M, a 31.75% change year over year.
  • Amylyx Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -117.59 M.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)